



## NEWS RELEASE

### TISSUE REGENERATION TECHNOLOGIES AND NONVASIV LAUNCH VETERINARY PRODUCT LINE

**March 13, 2007 (Woodstock, Georgia)** – Tissue Regeneration Technologies, LLC (TRT) and Nonvasiv, LLC (Nonvasiv) are proud to announce the launch of new two veterinary shockwave devices, the Vetwave140 and the Vetwave Portable. Both products allow anesthesia-free treatment, which is safer and less stressful for the patient and also reduces treatment costs.

The Vetwave140 is perfectly suited for the specific in-house requirements of veterinary clinics for treating horses and companion animals. Its broad spectrum of energy levels and variety of therapy heads enable treatment of equine and small animal indications ranging from tendon and musculoskeletal problems at low-energy settings to fractures and other bone disorders at high-energy settings. The Vetwave140 also employs Advanced ShockWave Technology (ASWT) developed exclusively by TRT's manufacturing and R&D subsidiary, MTS Europe GmbH. ASWT uses our patented SmartTrode "intelligent" electrode to combine the advantages of low-energy shockwave generation with those of high-energy in a single device without compromising the quality or consistency of the shockwaves being applied to the animal.

The Vetwave Portable device is a smaller, lightweight device created primarily for mobile equine practitioners and the small animal market. Developed by the key players who designed the current industry standard technology utilized at about 300 sites nationally, the Vetwave Portable employs innovative technology that serves the needs of veterinarians better than ever before by:

- further reducing the size and weight of the device to improve its use in the field;
- increasing the power range to accommodate a wider array of indications and species;
- utilizing a new patented flat-wave therapy head that enables pain-free shockwave therapy and eliminates the need for anesthesia (aside from increased patient safety, this significantly reduces the overall treatment cost); and
- reducing the cost of the device and extending the lifetime of associated consumables.

"Our goal has been to make shock wave therapy more affordable. By utilizing state-of-the-art design and production technologies we have done exactly that. Further, we are willing to aggressively support clinical research in both the equine and small animal market," stated Dr. Jens Stabler, CEO of Nonvasiv.

As announced last week, TRT and Nonvasiv agreed to merge, subject to certain conditions and due diligence by both parties. Since that announcement several orders for veterinary devices have been placed with the two companies. Also during the period of due diligence, the two

companies have reached an agreement to cross-license their patents, further strengthening their position in the veterinary market. The companies are also actively engaged in negotiations with several potential strategic partners and hope to announce resulting good news in the near future.

“We look forward to working together with clinicians and academics to further develop this exciting, non-invasive treatment modality,” commented John Warlick, TRT president.

“Ironically, the technology we plan to introduce to the veterinary market has already been tested extensively on *humans* – quite a change,” noted Warlick.

### **About TRT**

TRT is a leading-edge health care company that believes in “doing well by doing good.” Our state-of-the-art medical devices utilize MultiWave™ technology (a combination of heat, electromagnetic, acoustic, and light energies) to provide non-invasive and minimally invasive treatment for numerous pathological conditions, including chronic wounds, multiple periodontal applications, pseudoarthrosis and other avascular conditions of the bone, and ischemic heart disease. TRT is headquartered in suburban Atlanta, Georgia from which we operate our urology division, Shockwave Technical Service, and our cardiac subsidiary, Cardiac Regeneration Technologies. Production of our devices is handled by TRT’s manufacturing subsidiary, MTS Europe GmbH, located in Lake Constance, Germany. TRT has FDA clearance to market its LithoGold™ lithotripsy system for treatment of kidney and ureteral stones. Our devices are currently CE approved and distributed in approximately 20 countries throughout North America, Europe, Asia, Africa and South America. For more information, please visit the company’s website at [www.trtllc.com](http://www.trtllc.com).

### **About Nonvasiv**

Nonvasiv was formed by the founders and owners of SwiTech Medical, AG (Switzerland) and ITS, LLC (USA/Germany). Over the past two years these companies have jointly developed a new generation, low-cost, portable shockwave device. Last year over 60 devices were sold in Europe, Asia and South America. To commercialize this product on a broader scale and to combine respective know-how, client networks and IP rights, Nonvasiv, LLC was formed. Nonvasiv, LLC is located in Kennesaw, Georgia and its subsidiary Nonvasiv, GmbH is located in Konstanz, Germany.

Nonvasiv’s core strengths lie in technology, marketing and sales in the medical and veterinary businesses in Europe and the US. Nonvasiv’s management team has more than 75 years of experience in the shock wave business. Our R&D team includes the original developers of the current generation of successful veterinary shockwave devices. We are now launching the next generation shockwave device to reaffirm our leadership position in this technology.

To better serve the needs of the dermatology and companion animal markets, Nonvasiv has also developed and patented a flat wave treatment head. This is a major advancement in shockwave medicine which offers pain free treatment of current indications, while providing opportunity for a wider spectrum of new applications, the most immediate being companion animal medicine. For more information, please visit the company’s website at [www.nonvasiv.de](http://www.nonvasiv.de).

*Contact information:* TRT, Julie Dodd, (770) 966-1315 or [jdodd@trtllc.com](mailto:jdodd@trtllc.com)

*Contact information:* Nonvasiv, Jens Stabler, MD, (678) 641-5411 or [jens.stabler@nonvasiv.de](mailto:jens.stabler@nonvasiv.de)